Baseline characteristics of the 300 patients
| Characteristics | Overall (n = 300) | First-line chemotherapy regimen | P value | |
|---|---|---|---|---|
| GS (n = 84) | GnP (n = 216) | |||
| Gender | 0.324 | |||
| Male | 183 (61.0%) | 47 (56.0%) | 136 (63.0%) | |
| Female | 117 (39.0%) | 37 (44.0%) | 80 (37.0%) | |
| Age, median (range), years | 61 (32, 83) | 63 (38, 83) | 60 (32, 77) | 0.017 |
| ECOG | 0.112 | |||
| 0 | 156 (52.0%) | 48 (57.1%) | 108 (50.0%) | |
| 1 | 139 (46.3%) | 33 (39.3%) | 106 (49.1%) | |
| 2 | 5 (1.7%) | 3 (3.6%) | 2 (0.9%) | |
| BMI, median (range), kg/m2 | 21.6 (15.0, 35.3) | 21.6 (15.0, 27.6) | 21.5 (15.6, 35.3) | 0.978 |
| Smoking history | 0.081 | |||
| Yes | 122 (40.7%) | 27 (32.1%) | 95 (44.0%) | |
| No | 178 (59.3%) | 57 (67.9%) | 121 (56.0%) | |
| Drinking history | 0.121 | |||
| Yes | 70 (23.3%) | 14 (16.7%) | 56 (25.9%) | |
| No | 230 (76.7%) | 70 (83.3%) | 160 (74.1%) | |
| Diabetes history | 1.000 | |||
| Yes | 92 (30.7%) | 26 (31.0%) | 66 (30.6%) | |
| No | 208 (69.3%) | 58 (69.0%) | 150 (69.4%) | |
| Surgery before chemotherapy | 0.742 | |||
| Yes | 48 (16.0%) | 12 (14.3%) | 36 (16.7%) | |
| No | 252 (84.0%) | 72 (85.7%) | 180 (83.3%) | |
| CA19-9, median (range), U/mL | 418 (0, 400,000) | 343 (0, 400,000) | 478 (0.3, 86,900) | 0.300 |
| Baseline stage | 0.492 | |||
| Locally advanced | 111 (37.0%) | 28 (33.3%) | 83 (38.4%) | |
| Metastatic | 189 (63.0%) | 56 (66.7%) | 133 (61.6%) | |
| Liver metastases | 0.738 | |||
| Yes | 140 (46.7%) | 41 (48.8%) | 99 (45.8%) | |
| No | 160 (53.3%) | 43 (51.2%) | 117 (54.2%) | |
| Multiple metastases | 0.347 | |||
| Yes | 47 (15.7%) | 10 (11.9%) | 37 (17.1%) | |
| No | 253 (84.3%) | 74 (88.1%) | 179 (82.9%) | |